Dr. Martins has over 17 years U.S. and global biotechnology and pharmaceutical industry experience in translational clinical research, clinical development and medical affairs in various therapeutic areas, including HCV, HBV, influenza, allergy, immunology, and vaccines.
Dr. Martins was most recently the Senior Director, Medical Affairs for Hepatitis at Gilead Sciences where he oversaw a large global clinical trial in HBV, supervised multiple Phase 4 studies in viral hepatitis, and collaborations with drug discovery, translational research, and clinical development in viral hepatitis. Previously, he was the Senior International Medical Leader for Pegasys® (pegylated interferon alfa-2a) at Genentech/Roche. Prior to joining Genentech, Dr. Martins worked in positions of increasing responsibility at Dynavax Technologies, InterMune, and SciClone Pharmaceuticals, primarily focused on vaccines and therapeutics for viral hepatitis. Dr. Martins received an M.D. from the Medical School, Federal University of Rio de Janeiro, Brazil and a D.Phil. in Immunology of Liver Diseases from the University of Oxford, United Kingdom. He completed specialty training in Gastroenterology and Hepatology at John Radcliffe Hospital, Oxford, United Kingdom.